303 related articles for article (PubMed ID: 29476021)
21. Autologous transplantation for transformed non-Hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
Mei M; Wondergem MJ; Palmer JM; Shimoni A; Hasenkamp J; Tsai NC; Simpson J; Nademanee A; Raubitschek A; Forman SJ; Krishnan AY
Biol Blood Marrow Transplant; 2014 Dec; 20(12):2072-5. PubMed ID: 25079874
[TBL] [Abstract][Full Text] [Related]
22. Rituximab with dose-adjusted EPOCH as first-line treatment in patients with highly aggressive diffuse large B-cell lymphoma and autologous stem cell transplantation in selected patients.
Pejša V; Prka Ž; Lucijanić M; Mitrović Z; Piršić M; Jakšić O; Ajduković R; Kušec R
Croat Med J; 2017 Feb; 58(1):40-48. PubMed ID: 28252874
[TBL] [Abstract][Full Text] [Related]
23.
Conlon KC; Sportes C; Brechbiel MW; Fowler DH; Gress R; Miljkovic MD; Chen CC; Whatley MA; Bryant BR; Corcoran EM; Kurdziel KA; Pittaluga S; Paik CH; Lee JH; Fleisher TA; Carrasquillo JA; Waldmann TA
Cancer Biother Radiopharm; 2020 May; 35(4):249-261. PubMed ID: 32275165
[No Abstract] [Full Text] [Related]
24. Intensification treatment based on early FDG-PET in patients with high-risk diffuse large B-cell lymphoma: a phase II GELTAMO trial.
Pardal E; Coronado M; Martín A; Grande C; Marín-Niebla A; Panizo C; Bello JL; Conde E; Hernández MT; Arranz R; Bargay J; González-Barca E; Pérez-Ceballos E; Montes-Moreno S; Caballero MD
Br J Haematol; 2014 Nov; 167(3):327-36. PubMed ID: 25066542
[TBL] [Abstract][Full Text] [Related]
25. Bortezomib and Vorinostat Therapy as Maintenance Therapy Post-Autologous Transplant for Non-Hodgkin's Lymphoma Using R-BEAM or BEAM Transplant Conditioning Regimen.
Holmberg LA; Maloney DG; Connelly-Smith L
Acta Haematol; 2024; 147(3):300-309. PubMed ID: 37708877
[TBL] [Abstract][Full Text] [Related]
26. Busulfan-containing conditioning regimens are optimal preparative regimens for autologous stem cell transplant in patients with diffuse large B-cell lymphoma.
Shin HJ; Lee WS; Lee HS; Kim H; Lee GW; Song MK; Kim JS; Yhim HY; Chung JS
Leuk Lymphoma; 2014 Nov; 55(11):2490-6. PubMed ID: 24432893
[TBL] [Abstract][Full Text] [Related]
27. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
[TBL] [Abstract][Full Text] [Related]
28. Similar response rates and superior early progression-free survival with gemcitabine, dexamethasone, and cisplatin salvage therapy compared with carmustine, etoposide, cytarabine, and melphalan salvage therapy prior to autologous stem cell transplantation for recurrent or refractory Hodgkin lymphoma.
Kuruvilla J; Nagy T; Pintilie M; Tsang R; Keating A; Crump M
Cancer; 2006 Jan; 106(2):353-60. PubMed ID: 16329112
[TBL] [Abstract][Full Text] [Related]
29. De novo CD5+ diffuse large B-cell lymphoma: Adverse outcomes with and without stem cell transplantation in a large, multicenter, rituximab treated cohort.
Alinari L; Gru A; Quinion C; Huang Y; Lozanski A; Lozanski G; Poston J; Venkataraman G; Oak E; Kreisel F; Park SI; Matthews S; Abramson JS; Iris Lim H; Martin P; Cohen JB; Evens A; Al-Mansour Z; Singavi A; Fenske TS; Blum KA
Am J Hematol; 2016 Jun; 91(4):395-9. PubMed ID: 26800311
[TBL] [Abstract][Full Text] [Related]
30. Bortezomib maintenance after R-CHOP, cytarabine and autologous stem cell transplantation in newly diagnosed patients with mantle cell lymphoma, results of a randomised phase II HOVON trial.
Doorduijn JK; Zijlstra JM; Lugtenburg PJ; Kersten MJ; Böhmer LH; Minnema MC; MacKenzie MA; van Marwijk Kooij R; de Jongh E; Snijders TJF; de Weerdt O; van Gelder M; Hoogendoorn M; Leys RBL; Kibbelaar RE; de Jong D; Chitu DA; Van't Veer MB; Kluin-Nelemans HC
Br J Haematol; 2020 Aug; 190(3):385-393. PubMed ID: 32150297
[TBL] [Abstract][Full Text] [Related]
31. High-dose Bendamustine-EAM followed by autologous stem cell rescue results in long-term remission rates in lymphoma patients, without renal toxicity.
Noesslinger T; Panny M; Simanek R; Moestl M; Boehm A; Menschel E; Koller E; Keil F
Eur J Haematol; 2018 Sep; 101(3):326-331. PubMed ID: 29799642
[TBL] [Abstract][Full Text] [Related]
32. Yttrium-90-ibritumomab tiuxetan (Zevalin) combined with high-dose BEAM chemotherapy and autologous stem cell transplantation for chemo-refractory aggressive non-Hodgkin's lymphoma.
Shimoni A; Zwas ST; Oksman Y; Hardan I; Shem-Tov N; Yerushalmi R; Avigdor A; Ben-Bassat I; Nagler A
Exp Hematol; 2007 Apr; 35(4):534-40. PubMed ID: 17379063
[TBL] [Abstract][Full Text] [Related]
33. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
[TBL] [Abstract][Full Text] [Related]
34. Improving survival in patients with transformed B cell non Hodgkin lymphoma: consolidation with ⁹⁰Yttrium ibritumomab tiuxetan-BEAM and autologous stem cell transplantation.
Wondergem MJ; Zijlstra JM; de Rooij M; Visser OJ; Huijgens PC; Zweegman S
Br J Haematol; 2012 May; 157(3):395-7. PubMed ID: 22224561
[No Abstract] [Full Text] [Related]
35. Long-term follow-up of (90)Y-ibritumomab-tiuxetan ((90)YIT) in the conditioning of autologous hematopoietic transplantation for indolent and mantle cell lymphomas in a single French center.
Philippe L; Helias P; Puyraveau M; Boulahdour H; Deconinck E; Daguindau E
Bone Marrow Transplant; 2016 Aug; 51(8):1140-2. PubMed ID: 27042844
[No Abstract] [Full Text] [Related]
36. Long-Term Results with Thiotepa-Containing Conditioning Regimens for Autologous Stem Cell Transplantation.
Cohen YI; Lebel E; Zimran E; Shaulov A; Stepensky P; Grisariu S; Avni B
Transplant Cell Ther; 2023 Aug; 29(8):505.e1-505.e8. PubMed ID: 37160229
[TBL] [Abstract][Full Text] [Related]
37. High-dose therapy in diffuse large cell lymphoma: results and prognostic factors in 452 patients from the GEL-TAMO Spanish Cooperative Group.
Caballero MD; Pérez-Simón JA; Iriondo A; Lahuerta JJ; Sierra J; Marín J; Gandarillas M; Arranz R; Zuazu J; Rubio V; Fernández de Sevilla A; Carreras E; García-Conde J; García-Laraña J; Grande C; Sureda A; Vidal MJ; Rifón J; Pérez-Equiza C; Varela R; Moraleda JM; García Ruíz JC; Albó C; Cabrera R; San Miguel JF; Conde E
Ann Oncol; 2003 Jan; 14(1):140-51. PubMed ID: 12488306
[TBL] [Abstract][Full Text] [Related]
38. Randomised phase III study of R-ICE versus R-DHAP in relapsed patients with CD20 diffuse large B-cell lymphoma (DLBCL) followed by high-dose therapy and a second randomisation to maintenance treatment with rituximab or not: an update of the CORAL study.
Hagberg H; Gisselbrecht C;
Ann Oncol; 2006 May; 17 Suppl 4():iv31-2. PubMed ID: 16702182
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of DA-EPOCH-R induction plus autologous transplant consolidation for double hit lymphoma.
Chen AI; Leonard JT; Okada CY; Gay ND; Chansky K; Fan G; Dunlap JB; Raess PW; Braziel RM; Stentz A; Maziarz RT
Leuk Lymphoma; 2018 Aug; 59(8):1884-1889. PubMed ID: 29199519
[TBL] [Abstract][Full Text] [Related]
40. Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using
Mei M; Palmer J; Tsai NN; Simpson J; O'Hearn J; Stein A; Forman S; Spielberger R; Cai JL; Htut M; Nakamura R; Al Malki MM; Herrera A; Wong J; Nademanee A
Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):e268-e276. PubMed ID: 37301631
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
